NASDAQ$NAGE
Niagen Bioscience Inc · Q2 2025 earnings
Q2 2025 earnings · · After market close
Briefing
Niagen Bioscience Inc reported strong revenue growth and returned to profitability in Q2 2025.
The company posted net sales of $31.1 million for the three months ended June 30, 2025, representing a 37% increase year-over-year driven by growth in consumer products and ingredients. Net income reached $3.6 million compared to a net loss in the prior-year quarter, with operating income of $3.2 million. Cash and cash equivalents stood at $60.5 million at quarter end.
- Net sales rose 37% to $31.1 million, led by 22% growth in consumer products and 131% growth in ingredients.
- Net income of $3.6 million versus a $15,000 loss in Q2 2024, with basic EPS of $0.05.
- Gross profit increased 48% to $20.2 million, improving gross margin to 65%.
- Cash and cash equivalents grew to $60.5 million, supported by strong operating cash flow.
Headline financials
Revenue & EPS history
Niagen Bioscience Inc · Revenue · Quarterly
$31.1M
Revenue by segment
Niagen Bioscience Inc · $31.1M total across 3 segments · Q2 2025
- Tru Niagen Consumer Product$22.7M—72.9%
- Ingredients$7.62M—24.5%
- Analytical Reference Standards$799K—2.6%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+0.5%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+2.3%
Avg return
30 days after
56%
14 / 25 earnings
Positive
+7.3%
Q2 2022
Best reaction
-6.7%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +3.1% | -17.4% | -28.6% | |
| Q4 2025 | +3.2% | +5.7% | -11.3% | |
| Q3 2025 | -3.9% | -5.4% | -7.3% | |
| Q1 2025 | -3.2% | +7.6% | +48.3% | |
| Q3 2024 | -2.5% | +70.7% | +115.6% | |
| Q2 2024 | -6.7% | +0.0% | +18.1% | |
| Q1 2024 | +2.1% | -9.9% | -14.7% | |
| Q3 2023 | +4.6% | -11.1% | -12.4% | |
| Q2 2023 | -0.6% | -4.2% | -7.2% | |
| Q1 2023 | +5.8% | +9.4% | +14.4% | |
| Q3 2022 | +1.8% | +31.7% | +6.7% | |
| Q2 2022 | +7.3% | -8.3% | -25.5% | |
| Q1 2022 | +0.6% | +12.3% | +29.4% | |
| Q3 2021 | +2.2% | +0.3% | -32.1% | |
| Q2 2021 | -2.1% | -2.0% | -9.2% | |
| Q1 2021 | -3.9% | -20.7% | +0.1% | |
| Q3 2020 | +1.5% | +2.1% | +3.8% | |
| Q2 2020 | -4.3% | -7.2% | -12.1% | |
| Q1 2020 | +3.9% | +5.4% | -7.6% | |
| Q3 2019 | -0.7% | +11.6% | +38.2% | |
| Q2 2019 | -2.2% | -7.6% | -9.4% | |
| Q1 2019 | +1.9% | +0.4% | -12.0% | |
| Q3 2018 | +6.0% | -1.1% | -9.2% | |
| Q2 2018 | +2.3% | +0.0% | -18.3% | |
| Q1 2018 | -2.9% | -5.2% | -1.0% | |
| Q2 2011 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro